Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Melanoma 24Carcinoma, Renal Cell 15Stomach Neoplasms 9Lung Neoplasms 9Squamous Cell Carcinoma of Head and Neck 6Kidney Neoplasms 5Carcinoma, Hepatocellular 5Brain Neoplasms 5Urinary Bladder Neoplasms 4Mesothelioma 4Adenocarcinoma Of Esophagus 4Skin Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Anus Neoplasms 3Various Advanced Cancer 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Mesothelioma, Malignant 2Liver Neoplasms 2Hodgkin Disease 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma 2Anal Canal Carcinoma 2Adenocarcinoma 2von Hippel-Lindau Disease 1Uveal Melanoma 1

Interventions

Radiotherapy 5Mitomycin 5Fluorouracil 5Watchful Waiting 3Paclitaxel 3Nivolumab 3Cisplatin 3Vaccines 2Radiation 2Observation 2Light Coagulation 2Carboplatin 2Capecitabine 2pembrolizumab 1nanocis 1cemiplimab 1atezolizumab 1X-Rays 1Vaccines, Synthetic 1Technetium-99 1Taxes 1Specimen Handling 1Sigmoidoscopy 1Proctoscopy 1Phantoms, Imaging 1Papillomavirus Vaccines 1Octreotide 1Neoadjuvant Therapy 1Mitomycins 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Anus Neoplasms × Nivolumab × Clear all
NCT03233711 2026-05-13

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04444921 2026-05-04

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

National Cancer Institute (NCI)

Phase 3 Active not recruiting
205 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

University of Pittsburgh

Phase 3 Completed
161 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡